Corporate Profile

At Talis, we strive to deliver excellence in point of care diagnostics by increasing access to timely and accurate testing that can help combat the spread of known and emerging infectious diseases.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

11 Feb '21
MENLO PARK, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced the pricing of its initial public offering of 13,800,000 shares of
27 Jan '21
Clinician and Academician Brings Expertise in Women's and Adolescents' Health and Focus on Diversity, Equity, and Inclusion MENLO PARK, Calif., Jan. 27, 2021 /PRNewswire/ --  Talis Biomedical Corporation , a company dedicated to developing innovative molecular diagnostic tests for infectious

Recent Events

There are no events available at this time.